The filing desk starts with provenance, and Moderna’s annual report frames a company defined by what it is building rather than what it is selling. The Form 10-K for the year ended December 31, 2019 was filed on February 27, 2020 under accession number 0001682852-20-000006. Its revenue line is small by design: $60.2 million for 2019, down from $135.1 million in 2018, the kind of figure that reflects collaboration and grant arrangements rather than product sales.

The more telling number sits on the cost side. Research and development expense came to $496.3 million for 2019, up from $454.1 million in 2018 — a spending line that dwarfs revenue and that, in the company’s own structure, is the real measure of the enterprise. For a clinical-stage platform, R&D is not an expense to be minimized so much as the investment that constitutes the business.

The pipeline detail in the filing reinforces the read. The document catalogs programs across multiple therapeutic areas, citing activity measured in animal models for candidates including mRNA-3704 for methylmalonic acidemia, mRNA-3927 for propionic acidemia, mRNA-3283 for phenylketonuria, and mRNA-3745 for glycogen storage disease type 1a. These are early-stage descriptors — the language of a company whose value rests on programs still moving through development.

What the annual report does not contain is a commercial story, and the discipline is to say so plainly. As of this filing, Moderna is a pre-revenue-of-scale platform: the numbers describe research intensity, not a sales ramp. Any forward read belongs to the clinical milestones and partnerships the company is pursuing, not to a current-year revenue line that the filing itself keeps modest.

For a filing-first markets desk, that is the honest framing. The revenue and R&D figures and the named pipeline programs are pulled directly from the company’s own annual report rather than from a press summary. The discovery layer that surfaced the filing and its accession trail was SEC filings, the SEC filing data API and evidence index; the record itself is the SEC filing.

Provenance for this read: the primary source is Moderna’s Form 10-K for fiscal 2019 at sec.gov, with the revenue and period figures drawn from the structured XBRL data in the company’s own filing. See the SEC filing on sec.gov for the primary record, discovered via SEC filings, the SEC filing data API & evidence index.